FDA Adverse Event Injury Summary report: N

ENDEAVOR SPRINT RX

MDR report key: 2362934 · Received December 8, 2011

Report

Report Number
9612164-2011-01625
Event Type
Injury
Date Received
December 8, 2011
Date of Event
October 15, 2011
Report Date
November 21, 2012
Manufacturer
MEDTRONIC IRELAND
Product Code
NIQ
PMA / PMN Number
P060033
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
BR
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

LIPID LOWERING DRUGS, CLOPIDOGREL AND ASA. (B)(4). EVALUATION RESULTS (B)(4) INHERENT RISK OF PROCEDURE (MYOCARDIAL INFARCTION) MEDTRONIC, INC. (MEDTRONIC) IS SUBMITTING THIS REPORT TO COMPLY WITH 21 C.F.R. PART 803, THE MEDICAL DEVICE REPORTING REGULATION. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY MEDTRONIC, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. MEDTRONIC HAS MADE REASONABLE EFFORTS TO OBTAIN MORE COMPLETE INFORMATION IN THE TIME ALLOTTED AND HAS PROVIDED AS MUCH INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT.

Description of Event or Problem · 1

ADDITIONAL INFORMATION RECEIVED CONFIRMED THAT DURING THE INDEX PROCEDURE BOTH (B)(6) STUDY STENTS WERE IMPLANTED TO THE LAD.

Description of Event or Problem · 1

DURING INDEX PROCEDURE THE PATIENT HAD ONE ENDEAVOR SPRINT RAPID EXCHANGE (RX) DRUG-ELUTING STENT IMPLANTED TO THE MID RCA AND ONE ENDEAVOR SPRINT RX DRUG-ELUTING STENT IMPLANTED TO THE PROXIMAL RCA. THE FOLLOWING DAY THE PATIENT SUFFERED A MYOCARDIAL INFARCTION (MI). IT IS UNKNOWN WHETHER THE REPORTED MI WAS RELATED TO THE TARGET VESSEL. THE INVESTIGATOR INDICATED THAT THE REPORTED EVENT WAS POSSIBLY RELATED TO THE STUDY DEVICE. REF MFR# 9612164-2011-01624, 9612164-2011-01625

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ENDEAVOR SPRINT RX STENT, CORONARY, DRUG-ELUTING NIQ MEDTRONIC IRELAND 0002833292

Patients

Seq Age Sex Outcome Treatment
1 00050 YR Hospitalization BETA-BLOCKERS, ACE, CA++ ANTAGONIST